Suneel K. Gupta
Member of Scientific Advisory BoardDr. Suneel K. Gupta is Chief Scientific Officer of AmMax Bio, Inc. from September 2026. Dr. Gupta served as Executive Vice President of Clinical Development at Protagonist Therapeutics, Inc. from January 1, 2025 to 2026. Dr. Gupta is Member of Clinical Advisory Board of NuMedii, Inc. Dr. Gupta was Chief Development Officer of Protagonist Therapeutics, Inc. from January 07, 2019 to January 1, 2025 and served as its Executive Vice President of Clinical Pharmacology and Clinical Operations from January 2019 to May 2019. Dr. Gupta has R&D leadership that has overseen the delivery of more than a dozen FDA-approved medicines. Dr. Gupta, with expertise in hematology-oncology indications, will lead AmMax’s scientific strategy across its ADC portfolio, spanning translational science, clinical pharmacology, nonclinical development and regulatory strategy. Dr. Gupta joined AmMax from Protagonist Therapeutics, Inc., where he served as Chief Development Officer and Executive Vice President. He co-led global clinical development of MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic peptide that received FDA approval for adults with polycythemia vera in August 2026. Prior to that, Dr. Gupta served as Chief Scientific Officer at Impax Pharmaceuticals and led the development and U.S. approval of Rytary® and Crexont® for Parkinson’s disease. Earlier, at Johnson & Johnson and ALZA Corporation, Dr. Gupta co-chaired West Coast research and early development and invented Invega® and Concerta®. Across his career, he has led more than twelve novel products through registration and secured Breakthrough Therapy, Fast Track and Orphan Drug designations in the U.S. and EU. He serves as a Member of Scientific Advisory Board of TRxADE HEALTH, Inc. (formerly known as Scienture Inc.) He served as Member of Scientific Advisory Board at Unicycive Therapeutics, Inc. He served as an Executive Vice President of Clinical Operations and Clinical Pharmacology at Protagonist Therapeutics, Inc. from January 7, 2019 to January 2019. Dr. Gupta provides executive management and oversight of clinical operations and clinical pharmacology of development candidates in pipeline. With industry experience, Dr. Gupta has contributed to the development and commercialization of more than 12 products approved by both the U.S. FDA and the European Medicines Agency. Prior to joining Protagonist, he served as the Chief Scientific Officer of Impax Pharmaceuticals at Impax Laboratories Inc. since April 2008 to January 2019 and served as its Senior Vice President of R&D since May 23, 2017. Prior to Johnson & Johnson, Dr. Gupta worked at ALZA Corporation, a wholly-owned subsidiary of Johnson & Johnson, from 1989 to 2001, where he was responsible for strategic vision and execution of clinical research and development as Senior Vice President and distinguished research fellow from 2002 to 2008 and Vice President of Clinical Pharmacology & Product Discovery. Dr. Gupta has an extensive experience in development of drug delivery based products. He has been instrumental in the development of several marketed products including Duragesic(R), Nicoderm(R), Ditropan-XL(R), Concerta(R), Ionsys(R) and Invega(R). He is co-inventor on more than 20 patents related to drug discovery and drug delivery. He has served on the Scientific Advisory Board of the National Institute on Drug Abuse and on an FDA advisory panel. Dr. Gupta holds a Ph.D. in Pharmacokinetics from the University of Manchester, in Manchester, United Kingdom in 1987 and was a Post-Doctoral Fellow at the University of California, San Francisco under Professor Leslie Z. Benet.
Positions
- Company NameScienture Holdings, Inc.Stock CodeSCNXPositionMember of Scientific Advisory BoardColleagues
- SHShankar HariharanFounder, Co-CEO & Executive Chairman
- NMNarasimhan ManiPresident, Co-CEO, Interim CFO & Director
- RSRahul SuranaExecutive VP & COO of Scienture LLC
- MRMichele RathSenior VP & Chief Commercial Officer of Scienture LLC
- DGDonald G. FellIndependent Director
- MMMayur Mansukhlal DoshiIndependent Director
